Organon & (US:OGN) GlobeNewswire News Room·2025-07-07 20:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing significant adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - The company's regular quarterly dividend was reduced by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025 [3]. - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially be appointed as lead plaintiffs [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies engage in responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions [5].